In 2019, Ghasemi et al. analyzed 45 melanocytic tumors (20 malignant and 25 benign) and found that 65% of malignant tumors presented strong intensity of COX-2 labeling and that 35% had moderate intensity of labeling, which contrasts with our work, where we found 21% with strong and 26.3% with moderate intensities of labelling [62]. The gene discussed is PTGS2; the disease is cancer.